PE20181304A1 - Derivados de indol n-sustituidos como moduladores de los receptores de pge2 - Google Patents
Derivados de indol n-sustituidos como moduladores de los receptores de pge2Info
- Publication number
- PE20181304A1 PE20181304A1 PE2018000994A PE2018000994A PE20181304A1 PE 20181304 A1 PE20181304 A1 PE 20181304A1 PE 2018000994 A PE2018000994 A PE 2018000994A PE 2018000994 A PE2018000994 A PE 2018000994A PE 20181304 A1 PE20181304 A1 PE 20181304A1
- Authority
- PE
- Peru
- Prior art keywords
- carbon atoms
- alkyl
- methyl
- modulators
- cancer
- Prior art date
Links
- 102000008866 Prostaglandin E receptors Human genes 0.000 title 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- -1 cycloprop-1,1-di-yl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 201000010174 renal carcinoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un compuesto de la formula (I), en donde (R1)n representa 1 , dos o tres sustituyentes opcionales sobre el anillo de indol, en donde los sustituyentes se seleccionan independientemente a partir de alquilo (de 1 a 3 atomos de carbono, alcoxilo (de uno a 3 atomos de carbono), entre otros; R2 es alquilo (de 1 a 4 atomos de carbono), halogeno, o ciano; R3 es hidrogeno, metilo o trifluoro-metilo; R4a y R4b son independientemente hidrogeno, metilo, o R4a y R4b junto con el atomo de carbono con el que estan unidos, representan un grupo cicloprop-1,1-di-ilo; R5a y R5b son independientemente hidrogeno, metilo, o R5a y R5b junto con el atomo de carbono con el que estan unidos, representan un grupo cicloprop-1,1-di-ilo; Ar1 es fenilo o heteroarilo de 5 a 6 miembros, alquilo (de 1 a 6 atomos de carbono), alcoxilo (de 1 a 4 atomos de carbono), entre otros; estos son derivados de indol N-sustituidos. Tambien, se refiere a su preparacion, a sales farmaceuticamente aceptables de los mismos, composiciones farmaceuticas y a su uso como moduladores de los receptores de prostaglandina 2 (PGE2): EP2 y/o EP4. Se pueden utilizar como agentes individuales o en combinacion con uno o mas agentes terapeuticos, y/o con quimioterapia, en la prevencion o tratamiento de cancer, como el melanoma, cancer de pulmon, carcinomas renales, cancer gastrointestinal, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015077269 | 2015-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181304A1 true PE20181304A1 (es) | 2018-08-09 |
Family
ID=57326428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000994A PE20181304A1 (es) | 2015-11-20 | 2016-11-17 | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11241431B2 (es) |
| EP (2) | EP3928836B1 (es) |
| JP (2) | JP2018534328A (es) |
| KR (1) | KR102352022B1 (es) |
| CN (1) | CN108349949B (es) |
| AU (1) | AU2016358242B2 (es) |
| BR (1) | BR112018010291B1 (es) |
| CA (1) | CA3002610C (es) |
| CL (1) | CL2018001325A1 (es) |
| CO (1) | CO2018005715A2 (es) |
| CR (1) | CR20180323A (es) |
| CY (1) | CY1124913T1 (es) |
| DK (2) | DK3377483T3 (es) |
| EA (1) | EA037953B1 (es) |
| ES (2) | ES2897954T3 (es) |
| FI (1) | FI3928836T3 (es) |
| HR (2) | HRP20241521T1 (es) |
| HU (2) | HUE069520T2 (es) |
| IL (1) | IL259424B (es) |
| LT (2) | LT3377483T (es) |
| MA (2) | MA55046B1 (es) |
| MX (1) | MX375978B (es) |
| MY (1) | MY195888A (es) |
| PE (1) | PE20181304A1 (es) |
| PH (1) | PH12018501077A1 (es) |
| PL (2) | PL3377483T3 (es) |
| PT (2) | PT3928836T (es) |
| RS (2) | RS62598B1 (es) |
| SA (1) | SA518391588B1 (es) |
| SG (1) | SG11201803627XA (es) |
| SI (2) | SI3928836T1 (es) |
| TW (2) | TWI719078B (es) |
| UA (1) | UA123441C2 (es) |
| WO (1) | WO2017085198A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) * | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN110461823B (zh) | 2017-03-27 | 2023-08-11 | 魁北克电力公司 | 用于电解质组合物中或用作电极添加剂的盐 |
| WO2018210987A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| CA3060394A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
| CA3063788A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| CN109678780A (zh) * | 2017-10-19 | 2019-04-26 | 中国石油化工股份有限公司 | 一种制备3-烷基吲哚衍生物的方法 |
| JP2021503486A (ja) | 2017-11-20 | 2021-02-12 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物ならびに組成物および使用法 |
| AU2019205944A1 (en) | 2018-01-05 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3906028A4 (en) * | 2018-12-31 | 2022-10-12 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
| EP3693359A1 (en) * | 2019-02-08 | 2020-08-12 | Medibiofarma, S.L. | New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators |
| WO2021060281A1 (ja) * | 2019-09-24 | 2021-04-01 | Ａｇｃ株式会社 | プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト |
| EP4054719A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
| WO2022272062A1 (en) | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| DK1267867T3 (da) | 2000-03-24 | 2008-08-25 | Asterand Uk Ltd | Anvendelse af prostanoid-EP4-receptorantagonister til behandling af hovedpine og assays til sådanne antagonister |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| BR0309305A (pt) | 2002-04-12 | 2005-02-15 | Pfizer | Compostos de imidazol como agentes antiinflamatórios e analgésicos |
| WO2003087061A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Japan Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
| JP2006506327A (ja) | 2002-05-23 | 2006-02-23 | セラテクノロジーズ インコーポレイティド | プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド |
| CN100408570C (zh) | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
| EP1661897B1 (en) | 2003-08-26 | 2013-12-04 | Teijin Pharma Limited | Pyrrolopyrimidinone derivative |
| CN1867551B (zh) | 2003-09-03 | 2013-09-11 | 拉夸里亚创药株式会社 | 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物 |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EP1723132A1 (en) * | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| KR20070006891A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물 |
| ES2327760T3 (es) | 2004-05-04 | 2009-11-03 | Raqualia Pharma Inc | Compuestos de aril-heteroaril-amida ortosustituidos. |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| JP5289046B2 (ja) | 2005-05-19 | 2013-09-11 | メルク カナダ インコーポレイテッド | Ｅｐ４アンタゴニストとしてのキノリン誘導体 |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| DOP2007000068A (es) | 2006-04-12 | 2007-10-31 | Sanofi Aventis Us Llc | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
| CA2648729A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| AU2007260529B2 (en) | 2006-06-12 | 2012-04-19 | Merck Canada Inc. | Indoline amide derivatives as EP4 receptor ligands |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| RU2485115C2 (ru) | 2006-07-14 | 2013-06-20 | Новартис Аг | Производные пиримидина в качестве ингибиторов alk-5 |
| ES2421453T3 (es) | 2006-08-11 | 2013-09-02 | Merck Frosst Canada Ltd | Derivados de tiofenocarboxamida como ligandos del receptor EP4 |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| CN101622230B (zh) | 2007-02-26 | 2012-08-22 | 默克弗罗斯特加拿大有限公司 | 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物 |
| WO2008116304A1 (en) | 2007-03-26 | 2008-10-02 | Merck Frosst Canada Ltd. | Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists |
| CA2681861A1 (en) | 2007-03-26 | 2008-10-16 | Astellas Pharma Inc. | Ornithine derivative |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| WO2009005076A1 (ja) | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| EA020439B1 (ru) | 2007-10-12 | 2014-11-28 | Астразенека Аб | Ингибиторы циклинзависимых киназ |
| WO2009105220A1 (en) | 2008-02-19 | 2009-08-27 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| BRPI0912778B1 (pt) | 2008-05-14 | 2019-04-30 | Astellas Pharma Inc. | Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| CA2733247C (en) | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| WO2010032123A1 (en) | 2008-09-19 | 2010-03-25 | Biotechnology Research Corporation Limited | Triterpenoid compounds and methods of use thereof |
| US8685999B2 (en) | 2008-09-25 | 2014-04-01 | Merck Sharp & Dohme Corp. | Beta carboline sulphonylurea derivatives as EP4 receptor antagonists |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| WO2011063181A1 (en) | 2009-11-23 | 2011-05-26 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
| EP2571867B1 (en) | 2010-05-21 | 2015-11-04 | Noviga Research AB | Novel pyrimidine derivatives |
| PT2619182T (pt) | 2010-09-21 | 2017-01-17 | Eisai R&D Man Co Ltd | Composição farmacêutica |
| US9175080B2 (en) | 2010-09-29 | 2015-11-03 | Nb Health Laboratory Co., Ltd. | Antibody against human prostaglandin E2 receptor EP4 |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| KR20130116287A (ko) | 2010-11-17 | 2013-10-23 | 노파르티스 아게 | 3-(아미노아릴)-피리딘 화합물 |
| ES2545110T3 (es) | 2010-12-10 | 2015-09-08 | Rottapharm Biotech S.R.L. | Derivados de piridinamida como antagonistas del receptor EP4 |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| AU2012230229A1 (en) * | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
| WO2012149528A1 (en) | 2011-04-29 | 2012-11-01 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
| CA2839956A1 (en) | 2011-06-20 | 2012-12-27 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| AU2011372747B2 (en) | 2011-07-04 | 2016-12-22 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor antagonists |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| SI3459942T1 (sl) | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2711364A1 (en) * | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| MX373786B (es) | 2012-11-27 | 2020-03-23 | Thomas Helledays Stiftelse Foer Medicinsk Forskning | Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer. |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| KR102212981B1 (ko) | 2013-06-12 | 2021-02-04 | 가껭세이야꾸가부시기가이샤 | 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약 |
| MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
| ES2675027T3 (es) | 2013-09-06 | 2018-07-05 | Aurigene Discovery Technologies Limited | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| HRP20180804T1 (hr) | 2013-10-17 | 2018-08-10 | Vertex Pharmaceuticals Incorporated | Inhibitori dnk-pk |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| TR201904327T4 (tr) | 2013-12-17 | 2019-04-22 | Lilly Co Eli | Dimetilbenzoik asit bileşikleri. |
| KR101807981B1 (ko) | 2013-12-17 | 2017-12-11 | 일라이 릴리 앤드 캄파니 | 페녹시에틸 시클릭 아민 유도체 및 ep4 수용체 조절제로서의 그의 활성 |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| US10052332B2 (en) | 2014-04-29 | 2018-08-21 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| CN106572993B (zh) | 2014-05-23 | 2019-07-16 | 卫材R&D管理有限公司 | Ep4拮抗剂在制备治疗癌症的药物中的应用 |
| US10064869B2 (en) | 2014-06-04 | 2018-09-04 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| HUE052969T2 (hu) | 2015-01-09 | 2021-05-28 | Ono Pharmaceutical Co | Triciklusos spiro vegyület |
| DK3325490T3 (da) | 2015-07-23 | 2020-02-03 | Takeda Pharmaceuticals Co | 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister |
| EP3362454B1 (en) | 2015-10-16 | 2021-12-08 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP4219462A1 (en) | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| HRP20211532T1 (hr) | 2017-05-18 | 2022-01-07 | Idorsia Pharmaceuticals Ltd | N-supstituirani derivati indola |
| WO2018210987A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| CA3060394A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
| CA3063788A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
-
2015
- 2015-11-20 CR CR20180323A patent/CR20180323A/es unknown
-
2016
- 2016-11-17 RS RS20211424A patent/RS62598B1/sr unknown
- 2016-11-17 DK DK16797577.0T patent/DK3377483T3/da active
- 2016-11-17 RS RS20241254A patent/RS66179B1/sr unknown
- 2016-11-17 SI SI201631863T patent/SI3928836T1/sl unknown
- 2016-11-17 PL PL16797577T patent/PL3377483T3/pl unknown
- 2016-11-17 PL PL21186831.0T patent/PL3928836T3/pl unknown
- 2016-11-17 WO PCT/EP2016/078028 patent/WO2017085198A1/en not_active Ceased
- 2016-11-17 MX MX2018005268A patent/MX375978B/es active IP Right Grant
- 2016-11-17 PT PT211868310T patent/PT3928836T/pt unknown
- 2016-11-17 MA MA55046A patent/MA55046B1/fr unknown
- 2016-11-17 FI FIEP21186831.0T patent/FI3928836T3/fi active
- 2016-11-17 ES ES16797577T patent/ES2897954T3/es active Active
- 2016-11-17 EP EP21186831.0A patent/EP3928836B1/en active Active
- 2016-11-17 CA CA3002610A patent/CA3002610C/en active Active
- 2016-11-17 LT LTEPPCT/EP2016/078028T patent/LT3377483T/lt unknown
- 2016-11-17 SG SG11201803627XA patent/SG11201803627XA/en unknown
- 2016-11-17 AU AU2016358242A patent/AU2016358242B2/en active Active
- 2016-11-17 HU HUE21186831A patent/HUE069520T2/hu unknown
- 2016-11-17 MA MA43251A patent/MA43251B1/fr unknown
- 2016-11-17 SI SI201631400T patent/SI3377483T1/sl unknown
- 2016-11-17 LT LTEP21186831.0T patent/LT3928836T/lt unknown
- 2016-11-17 PE PE2018000994A patent/PE20181304A1/es unknown
- 2016-11-17 CN CN201680066933.8A patent/CN108349949B/zh active Active
- 2016-11-17 KR KR1020187017474A patent/KR102352022B1/ko active Active
- 2016-11-17 US US15/777,597 patent/US11241431B2/en active Active
- 2016-11-17 UA UAA201806812A patent/UA123441C2/uk unknown
- 2016-11-17 HU HUE16797577A patent/HUE056679T2/hu unknown
- 2016-11-17 EA EA201891179A patent/EA037953B1/ru unknown
- 2016-11-17 MY MYPI2018701873A patent/MY195888A/en unknown
- 2016-11-17 JP JP2018526184A patent/JP2018534328A/ja not_active Ceased
- 2016-11-17 EP EP16797577.0A patent/EP3377483B9/en active Active
- 2016-11-17 DK DK21186831.0T patent/DK3928836T3/da active
- 2016-11-17 ES ES21186831T patent/ES2994636T3/es active Active
- 2016-11-17 HR HRP20241521TT patent/HRP20241521T1/hr unknown
- 2016-11-17 HR HRP20211678TT patent/HRP20211678T1/hr unknown
- 2016-11-17 PT PT167975770T patent/PT3377483T/pt unknown
- 2016-11-17 BR BR112018010291-1A patent/BR112018010291B1/pt active IP Right Grant
- 2016-11-18 TW TW105137938A patent/TWI719078B/zh active
- 2016-11-18 TW TW109133855A patent/TWI754397B/zh active
-
2018
- 2018-05-15 SA SA518391588A patent/SA518391588B1/ar unknown
- 2018-05-16 IL IL259424A patent/IL259424B/en active IP Right Grant
- 2018-05-17 CL CL2018001325A patent/CL2018001325A1/es unknown
- 2018-05-18 PH PH12018501077A patent/PH12018501077A1/en unknown
- 2018-05-30 CO CONC2018/0005715A patent/CO2018005715A2/es unknown
-
2021
- 2021-04-13 JP JP2021067831A patent/JP7228618B2/ja active Active
- 2021-11-30 CY CY20211101035T patent/CY1124913T1/el unknown
- 2021-12-13 US US17/549,828 patent/US12011444B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| AR080467A1 (es) | Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20170247A1 (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1 | |
| AR078303A1 (es) | Sulfonas sustituidas que modulan selectivamente el receptor cb2 | |
| PE20191811A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
| EA201490722A1 (ru) | ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5 | |
| PE20191814A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| PE20141000A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| CO2019010804A2 (es) | Derivados de indol n–sustituidos | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| AR102972A1 (es) | Compuestos de dihidropirimidin-2-ona y su uso médico | |
| PE20191032A1 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos | |
| AR096490A1 (es) | Moduladores del receptor cxcr7 | |
| PE20141527A1 (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos |